[1] Forner A,Reig M,Bruix J. Hepatocellular carcinoma. Lancet, 2018, 391: 1301-1314.
[2] Llovet JM,Kelley RK,Villanueva A,et al. Hepatocellular carcinoma. Nat Rev Dis Primers, 2021, 7: 6.
[3] 张鹭,江建宁. 原发性肝癌发病机制和治疗的最新进展. 肝脏, 2020, 25: 455-458.
[4] Marin JJG,Macias RIR,Monte MJ,et al. Molecular bases of drug resistance in hepatocellular carcinoma. Cancers (Basel), 2020, 12: 1663.
[5] Ye J,Xu M,Tian X,et al. Research advances in the detection of miRNA. J Pharm Anal, 2019, 9: 217-226.
[6] Morishita A,Oura K,Tadokoro T,et al. MicroRNAs in the pathogenesis of hepatocellular carcinoma: a review. Cancers (Basel), 2021, 13: 514.
[7] Wang M,Yu F,Chen X,et al. The underlying mechanisms of noncoding RNAs in the chemoresistance of hepatocellular carcinoma. Mol Ther Nucleic Acids, 2020, 21: 13-27.
[8] Ghafouri-Fard S,Honarmand Tamizkar K,Hussen BM,et al. MicroRNA signature in liver cancer. Pathol Res Pract, 2021, 219: 153369.
[9] Sulas P,Di Tommaso L,Novello C,et al. A large set of miRNAs is dysregulated since the earliest steps of human hepatocellular carcinoma development. Am J Pathol, 2017, doi: 10.1016/j.ajpath.2017.10.024.
[10] Tian LL,Qian B,Jiang XH,et al. MicroRNA-497-5p is downregulated in hepatocellular carcinoma and associated with tumorigenesis and poor prognosis in patients. Int J Genomics, 2021, 2021: 6670390.
[11] Wang Q,Wang G,Niu L,et al. Exosomal miR-1290 promotes angiogenesis of hepatocellular carcinoma via targeting SMEK1. J Oncol, 2021, 2021: 6617700.
[12] Chen C,Zong Y,Tang J,et al. miR-369-3p serves as prognostic factor and regulates cancer progression of hepatocellular carcinoma. Per Med, 2021, 18: 375-388.
[13] Yang X,Yang S,Song J,et al. Dysregulation of miR-23b-5p promotes cell proliferation via targeting FOXM1 in hepatocellular carcinoma. Cell Death Discov, 2021, 7: 47.
[14] Lee NY,Suk KT. The role of the gut microbiome in liver cirrhosis treatment. Int J Mol Sci, 2020, 22: 199.
[15] Li X,Guo Y,Wang X,et al. Clinical significance of serum miR-487b in HBV-related hepatocellular carcinoma and its potential mechanism. Infect Dis (Lond), 2021, 53:546-554.
[16] Liu Z,Sun J,Wang X,et al. MicroRNA-129-5p promotes proliferation and metastasis of hepatocellular carcinoma by regulating the BMP2 gene. Exp Ther Med, 2021, 21: 257.
[17] Cao X,Zhang J,Apaer S,et al. microRNA-19a-3p and microRNA-376c-3p promote hepatocellular carcinoma progression through SOX6-mediated wnt/beta-catenin signaling pathway. Int J Gen Med, 2021, 14: 89-102.
[18] Lai Y,Feng B,Abudoureyimu M,et al. Non-coding RNAs: emerging regulators of sorafenib resistance in hepatocellular carcinoma. Frontiers in oncology, 2019, 9: 1156.
[19] Kudo M. Systemic therapy for hepatocellular carcinoma: 2017 update. Oncology, 2017, 93 Suppl 1: 135-146.
[20] Dietrich P,Koch A,Fritz V,et al. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut, 2018, 67: 1328-1341.
[21] Han T,Zhang Y,Yang X,et al. miR-552 regulates liver tumor-initiating cell expansion and sorafenib resistance. Mol Ther Nucleic Acids, 2020, 19: 1073-1085.
[22] Kabir TD,Ganda C,Brown RM,et al. A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. Hepatology, 2018, 67: 216-231.
[23] Wan Z,Liu T,Wang L,et al. MicroRNA-216a-3p promotes sorafenib sensitivity in hepatocellular carcinoma by downregulating MAPK14 expression. Aging (Albany NY), 2020, 12: 18192-18208.
[24] Zhao W,Ma B,Tian Z,et al. Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance. Br J Cancer, 2021, 124: 1237-1248.
[25] Li D,Wang T,Sun FF,et al. MicroRNA-375 represses tumor angiogenesis and reverses resistance to sorafenib in hepatocarcinoma. Cancer Gene Ther, 2021, 28: 126-140.
[26] Li J,Zhong X,Wang X,et al. miR-93 regulates liver tumor initiating cells expansion and predicts chemotherapeutic response of patients. Arch Biochem Biophys, 2021, 703: 108871.
[27] Wei L,Wang X,Lv L,et al. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma. Mol Cancer, 2019, 18: 147.
[28] Zeng T,Luo L,Huang Y,et al. Upregulation of miR-138 increases sensitivity to cisplatin in hepatocellular carcinoma by regulating EZH2. Biomed Res Int, 2021, 2021: 6665918.
[29] Li Y,Zhang Y,Zhang S,et al. circRNA circARNT2 suppressed the sensitivity of hepatocellular carcinoma cells to cisplatin by targeting the miR-155-5p/PDK1 Axis. Mol Ther Nucleic Acids, 2021, 23: 244-254.
[30] Liu Z,Dang C,Xing E,et al. Overexpression of CASC2 improves cisplatin sensitivity in hepatocellular carcinoma through sponging miR-222. DNA Cell Biol, 2019, 38: 1366-1373.
[31] Cui X,Zhou D,Du Q,et al. MicroRNA200a enhances antitumor effects in combination with doxorubicin in hepatocellular carcinoma. Transl Oncol, 2020, 13: 100805.
[32] Yuan YL,Yu H,Mu SM,et al. MiR-26a-5p inhibits cell proliferation and enhances doxorubicin sensitivity in HCC cells via targeting AURKA. Technol Cancer Res Treat, 2019, 18: 1533033819851833.
[33] Gao X,Jiang Y,Li Y. Inhibitory effect of miR-140-5p on doxorubicin resistance of hepatocellular carcinoma. Exp Ther Med, 2021, 21: 507. |
